Matinas BioPharma (MTNB) Sees Unusually-High Trading Volume

Share on StockTwits

Shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) saw unusually-strong trading volume on Friday . Approximately 4,908,119 shares changed hands during mid-day trading, an increase of 304% from the previous session’s volume of 1,214,606 shares.The stock last traded at $1.30 and had previously closed at $1.20.

Separately, Roth Capital started coverage on shares of Matinas BioPharma in a research note on Monday, February 11th. They issued a “buy” rating and a $4.75 target price on the stock.

A number of institutional investors have recently modified their holdings of MTNB. D. E. Shaw & Co. Inc. bought a new stake in Matinas BioPharma during the fourth quarter worth about $26,000. Private Advisor Group LLC lifted its position in shares of Matinas BioPharma by 100.4% during the fourth quarter. Private Advisor Group LLC now owns 49,850 shares of the company’s stock worth $30,000 after purchasing an additional 24,978 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Matinas BioPharma during the fourth quarter worth approximately $39,000. Northern Trust Corp lifted its position in shares of Matinas BioPharma by 18.9% during the fourth quarter. Northern Trust Corp now owns 182,641 shares of the company’s stock worth $109,000 after purchasing an additional 29,072 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Matinas BioPharma by 325.6% during the third quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $124,000 after purchasing an additional 103,200 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Matinas BioPharma (MTNB) Sees Unusually-High Trading Volume” was originally published by Zolmax and is the sole property of of Zolmax. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://zolmax.com/investing/matinas-biopharma-mtnb-sees-unusually-high-trading-volume/2966107.html.

Matinas BioPharma Company Profile (NYSEAMERICAN:MTNB)

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Further Reading: Investing in Blue-Chip Stocks

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Guess?, Inc.  Receives Consensus Recommendation of “Hold” from Analysts
Guess?, Inc. Receives Consensus Recommendation of “Hold” from Analysts
Amazon.com, Inc.  CEO Sells $1,858,250.00 in Stock
Amazon.com, Inc. CEO Sells $1,858,250.00 in Stock
Alnylam Pharmaceuticals  Receives “Neutral” Rating from Goldman Sachs Group
Alnylam Pharmaceuticals Receives “Neutral” Rating from Goldman Sachs Group
Dimensional Fund Advisors LP Has $62.58 Million Holdings in AngioDynamics, Inc.
Dimensional Fund Advisors LP Has $62.58 Million Holdings in AngioDynamics, Inc.
Huntington Ingalls Industries Inc  Shares Bought by Dimensional Fund Advisors LP
Huntington Ingalls Industries Inc Shares Bought by Dimensional Fund Advisors LP
Intel Co.  Shares Bought by ETF Managers Group LLC
Intel Co. Shares Bought by ETF Managers Group LLC


 
© 2006-2019 Zolmax.